Literature DB >> 1690802

Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats.

S Fujimoto1, T Matsuda.   

Abstract

Effects of pimobendan (PBD) were investigated on isolated rat blood vessels. PBD dose-dependently relaxed aortic, femoral arterial and mesenteric venous preparations precontracted with KCl and reduced the amplitude of spontaneous contractions of portal venous preparations; the sensitivity to PBD was femoral greater than portal greater than mesenteric greater than aorta. Relaxation response of the femoral artery to PBD was not changed by propranolol and aminophylline. Glyceryl trinitrate (GTN), isoproterenol (ISO), forskolin and adenosine also elicited dose-dependent relaxations of femoral arteries; the rank order of potency (mean negative log EC50 value) was GTN greater than ISO greater than PBD = forskolin greater than adenosine. The relaxation responses to PBD and isobutyl methylaxanthine (IBMX) were not attenuated with removal of endothelial cells. In the femoral artery, methylene blue diminished GTN-induced relaxation but not PBD-induced relaxation. PBD and IBMX increased the relaxation responses of the artery to cyclic AMP-forming drugs (ISO, forskolin and adenosine) but not a cyclic GMP-forming drug (GTN). PBD and IBMX increased the relaxation response of mesenteric veins to ISO. The drugs noncompetitively inhibited arterial contractions accompanied by voltage-dependent and alpha-adrenoceptor-operated Ca2+ influxes. In the absence of extracellular Ca2+, PBD and IBMX reduced contractile responses of arteries to norepinephrine but not caffeine. The present results suggested that PBD relaxed the blood vessels, at least in part, through an intracellular accumulation of cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690802

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Selective blockade of nicotinic acetylcholine receptors by pimobendan, a drug for the treatment of heart failure: reduction of catecholamine secretion and synthesis in adrenal medullary cells.

Authors:  Yumiko Toyohira; Tatsuhiko Kubo; Miyabi Watanabe; Yasuhito Uezono; Susumu Ueno; Koji Shinkai; Masato Tsutsui; Futoshi Izumi; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-02-16       Impact factor: 3.000

Review 2.  Calcium sensitising agents in heart failure.

Authors:  L Mathew; S D Katz
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

3.  Study of NO and VIP as non-adrenergic non-cholinergic neurotransmitters in the pig gastric fundus.

Authors:  R A Lefebvre; G J Smits; J P Timmermans
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 4.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

5.  Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells.

Authors:  Y Xiong; E W Westhead; L L Slakey
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.